TG Therapeutics

J.P. Morgan Healthcare Conference

January 2020

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and TG Therapeutics undertakes no obligation to update these statements, except as required by law.

Fearless Pursuit

- Founded 8 years ago with one goal in mind… to create the best possible treatment options for patients with B-Cell diseases

- Focused on Cancer & Autoimmune disease with registration programs ongoing in:
  - Chronic Lymphocytic Leukemia
  - Marginal Zone Lymphoma
  - Follicular Lymphoma
  - Multiple Sclerosis

125	4	5	35	5	1
EMPLOYEES	OFFICES	MEDICINES UNDER DEVELOPMENT	CLINICAL TRIALS	REGISTRATION-DIRECTED AND PHASE 3 CLINICAL TRIALS	GOAL: TO CURE B-CELL DISEASES

B-Cell Focused Platform

Clinical Stage Portfolio Overview

Drug Candidate	Mechanism of Action	Stage of Development
Umbralisib (TGR-1202)	PI3Kδ/CK1ε	Phase 3
Ublituximab (TG-1101)	Anti-CD20	Phase 3
Cosibelimab (TG-1501)	Anti-PD-L1	Phase 1b
TG-1701	BTKi	Phase 1
TG-1801	Anti-CD47/CD19	Phase 1

UNITY-NHL MZL & FL
Rolling Submission Initiated!



TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

February 28, 2019 07:00 ET | Source:

Study met the primary endpo

Interim data to be presented

Umbralisib was previously gr

Conference call to be held to

NEW YORK, Feb. 28, 2019 (G
diseases, today announced t
delta inhibitor, met the prima
Company's target guidance o

Interi
April
Admi
by the

Micha
lymph

Profile

TG Therapeutics Announces Positive Results from the UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma

Email | Print Friendly | Share

October 28, 2019 07:00 ET | **Source:** TG Therapeutics, Inc.

Follicular lymphoma cohort met the primary endpoint of overall response rate (ORR)

Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports

TODAY!
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma

2020: Transformational Year w/ Multiple Pivotal Data Sets

UNITY-NHL Rel/Ref MZL and FL	UNITY-CLL Front Line & Rel/Ref	ULTIMATE I & II Relapsing MS
– Umbralisib Monotherapy –	*– Umbralisib + Ublituximab (U2) –*	*– Ublituximab Monotherapy –*
Positive Topline ORR Data	Trial Conduced Under SPA	Trials Conducted under SPA
BTD & ODD Granted for MZL	Enrolled ~420 patients	Enrolled Over 1100 Patients
Rolling Submission Initiated, Target 1H 2020 Completion	**Awaiting PFS Data, Target Q1 2020**	**Awaiting ARR Data, Target 2nd Half 2020**

- *Potential for Approvals in MZL, FL, CLL, SLL and MS from 2020 to 2022*
- *Commercial Preparations Underway*

Umbralisib:

Investigational Targeted Therapy with "Best-in-Class" Potential

Next Generation Dual PI3K-delta & CK1-epsilon Inhibitor

- *Demonstrated activity across NHL and CLL*
- *Potentially improved tolerability profile over 1st generation compounds*
- *Once daily v. twice daily for 1st generation compounds*

Data Supporting Umbralisib NDA In Previously Treated MZL-*Breakthrough Therapy Designation Granted*



MZL Preliminary Safety & Tolerability

- Umbralisib was deemed to be well tolerated
- No events of colitis reported
- AE's leading to dose reduction occurred in 6 subjects (9%)
- 10 subjects (14%) discontinued umbralisib due to an AE considered at least possibly related to treatment
- No deaths occurred on study
- Grade 3 infections were limited, occurring in 3 patients (bronchitis, pneumonia, and influenza)

- MZL trial met primary endpoint exceeding target 40% ORR amongst all patients (n=69)
- ***INITIATED ROLLING SUBMISSION!***

Fowler N, et. al., ASCO 2019

UNITY-NHL Umbralisib Monotherapy
Follicular Lymphoma (FL)

- **TG received guidance from the FDA allowing submission of a single NDA for Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) indications**
- Follicular Cohort Met Primary End Point
  - Exceeding 40% ORR hurdle
- Umbralisib monotherapy appeared to be well tolerated with a safety profile consistent with previous reports
- Other PI3K delta's obtained accelerated approved with similar efficacy (range: 42% - 59% ORR)

UNITY-NHL Trial
FL Cohort

Fully Enrolled

Umbralisib (TGR-1202) Monotherapy

Full Enrollment Complete	
Target ORR	40-50%
Enrollment Complete	3Q-18
Target Full Data Presentation	2020

MZL/FL: Incurable Disease with Limited Treatment Options

- Two largest forms of indolent NHL
- ~22,500 new cases per year[1] in MZL and FL
- ~6,000-10,000[2] relapsed indolent patients needing treatment each year

- **R²:** recently approved Revlimid plus Rituxan– can cause severe neutropenia and rash; secondary malignancy risks
- **Ibrutinib:** accelerated approval – less than half of patients respond; tolerability issues
- **PI3K Delta inhibitors:** none approved for MZL; 3 approved for FL tolerability issues have limited use

- Need for highly active, well-tolerated treatment option for MZL and FL

- **Umbralisib: Convenient oral daily dosing appears well tolerated with ~40-50% ORR in iNHL**

Source: 1. American Cancer Society 2019 2. Putnam Research 2018

Ublituximab:

Investigational Next Generation Anti-CD20 Monoclonal Antibody



US REGULATORY SUBMISSION PLAN

CLL *(in combo with umbralisib)*	**1H 2020**
Multiple Sclerosis	**YE 2020**

Ublituximab
Glycoengineered for enhanced potency over 1st generation
Activity in rituximab refractory patients
Shorter infusions than all other anti-CD20s (1-1.5 v 3-4 hours)

Early Clinical Data for Umbralisib and U2 in CLL Support Phase 3

87% ORR

Rel/Ref CLL
U2 after three months
In U2+Ven Phase 1 (n=23)

PFS: Rel/Ref CLL

Drug/Trial	PFS (mo.)
Umbralisib Phase 1	24
Umbralisib in BTK Intolerant	23.5
U2 Phase 1	28

UNITY-CLL



Study Enrollment	~420
Primary Endpoint	PFS
Target PFS Readout	1Q20
Patient Population	1L/2L+

Conducted under Special Protocol Assessment

TG Therapeutics

Barr et al., ASH 2019; Burris et al., 2018; Mato A, et. al, Lugano 2019; Lunning et al., 2019

CLL Market Opportunity

One of the Fastest Growing Global Hematology Markets

- ~115,000 Americans living with CLL
- ~20,000 newly-diagnosed patients each year
- ~20,000 previously treated patients seeking treatment each year



*Evaluate Pharma

U2 Has the Potential to Address Unmet Needs in CLL

- **Over 60,000 patients** in the US have been treated with a BTK-inhibitor creating a large population in the post-BTK setting in need of treatment options
- **~20% of treatment naïve patients will be deemed poor candidates** for BTK inhibitors due to potential safety/tolerability concerns
- **Up to 40% of patients will discontinue** BTK inhibitors for efficacy/tolerability issues at median of 17 months from starting therapy in recent real-world analysis
- **Venetoclax represents a challenge for community practices** due to enhanced monitoring and hospitalization to avoid TLS

➢ ***Substantial need for additional highly active, well-tolerated treatments for CLL***

TG Internal Research; Mato et al., 2018

B-Cell Platform Provides Next Gen Combo's

U2+TG-1701:
- Rel/Ref MZL/FL
- 100% ORR at lowest dose tested of 1701

U2+Venetoclax:
- Rel/Ref CLL
- 100% PB MRD-
- Best reported to date

Ublituximab + Umbralisib (U2) + Ibrutinib

Response Rate Observed with Triple Therapy

Type	Pts (n)	CR† (n)	PR (n)	ORR n (%)
CLL/SLL	19	6	13	19 (100%)
MZL	2	1	1	2 (100%)
MCL	4	2	2	4 (100%)
FL	5	1	3	4 (80%)
DLBCL	6	-	1	1 (17%)
Total	**36**	**10**	**20**	**30 (83%)**

Nastoupil et al, Lugano 2017

Ublituximab + Umbralisib + Pembro

Response Rate Observed with Triple Therapy

Group	N	CR N (%)	PR N (%)	ORR N (%)
CLL	10	1 (10%)	8 (80%)	**9 (90%)**
RT	4	2 (50%)	0	**2 (50%)**

Mato, et al. ASH 2018

Ublituximab in Relapsing Forms of Multiple Sclerosis

- ~1M Americans living with MS
- Completed Phase 2, data presented at multiple conferences
- Fully Enrolled Phase 3 ULTIMATE Trials
  - Special Protocol Assessment (SPA)
    - **Topline Data Targeted for 2H 2020**



MS – Phase 2 ARR Comparison



- **Final Ublituximab Phase 2 Data at Week 48**
  - 48 patients through 48 weeks of treatment
  - Annualized Relapse Rate of .07

TG Therapeutics

Fox et. al., ECTRIMS October 2018; Kappos L et al. Lancet. 2011; 378:1779-1787; Hauser SL et al. NEJM. 2017; 376:221-234

Ublituximab Phase 2: MRI-Gd Enhancing Lesions



- **No T1 Gd-enhancing lesions were detected in any subjects at Week 24 or Week 48 (100% reduction; p=0.003)**

Subject T1 Gd MRI at Baseline, Week 24 & Week 48



Fox E et al., ECTRIMS 2018

Significant Opportunity for Ublituximab in MS



Global Prevalence = ~2.3Million

Global Market Size >$30Billion by 2025

- **Ocrelizumab >$2 Billion in 2018 annual sales; on track to achieve ~$4B in 2019**

Source: Datamonitor 2018 MS Report; Prevalence Estimate: Nat'l MS Society; Roche JPM 2018 Corporate Update

Multiple Treatment Options Coexist & Account for Meaningful Market Share

Class	Drug	U.S. Approval Date	Route of Administration	Dosing	Global 2018 Revenues by Drug/Class ($ in millions)
Interferons	Betaseron	1993	Subcutaneously	1x / 2 days	$643
	Avonex (interferón beta-1a)	1996	Intramuscularly	1x / week	$1,915
	Rebif	2002	Subcutaneously	3x / week	$1,732
	Extavia	2009	Subcutaneously	1x / 2 days	$162
	Plegridy (peginterferon beta-1a)	2014	Subcutaneously	1x / 2 weeks	$448
IV Potent Immunomodulators	Tysabri (natalizumab)	2004	Intravenously	1x / 4 weeks	$1,864
	Lemtrada (alemtuzumab)	2014	Intravenously	3x / year	$475
T-Cell Targeted Orals	Gilenya (fingolimod)	2010	Orally	1x / day	$3,380
	Aubagio (teriflunomide)	2012	Orally	1x / day	$1,945
	Tecfidera (dimethyl fumarate)	2013	Orally	2x / day	$4,274
CD20s	Ocrevus (ocrelizumab)	2017	Intravenously	2x / year	$2,406
	Ofatumumab	2020	Subcutaneously	1x / 4 weeks	TBD
	Ublituximab	2021	Intravenously	2x / year	TBD

Source: Evaluate Pharma, Wall Street Research

Ublituximab Potential Value Proposition in MS

- Equal to better activity with comparable safety
- Convenience of 1 hour infusion every 6 months v. 3-4 hours for Ocrelizumab
- Strategically priced to optimize patient access
- ***Estimate $1-2B annual market opportunity in the US alone for ublituximab in MS***

Targeted Key Data & Potential Filings/Approvals



Corporate & Financial

Key Financial Statistics

Ticker:	TGTX (NASDAQ)
Price:	$14.10 (close on 1/15/2020)
Shares:	~112M (fully-diluted, as of 12/31/19)
Cash:	~$140M (as of 12/31/19)

TG Therapeutics

NASDAQ: TGTX